Indications And Dose
Oestrogen-receptor-positive breast cancer ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 500 mg every 2 weeks for the first 3 doses, then 500 mg every month, to be administered into the buttock
PDF page 1026
Loading InternPractice…
Drug reference
Oestrogen-receptor-positive breast cancer ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 500 mg every 2 weeks for the first 3 doses, then 500 mg every month, to be administered into the buttock
PDF page 1026
NICE decisions ▶Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (January 2018) NICE TA503 Fulvestrant is not recommended, within its marketing authorisation, for treating locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/ta503
PDF page 1026
→Appendix 1: fulvestrant
PDF page 1026
▶Common or very common Appetite decreased. arthralgia. asthenia. diarrhoea. headache. hot flush. hypersensitivity . increased risk of infection. nausea. pain. rash. vaginal haemorrhage. venous thromboembolism. vomiting ▶Uncommon Hepatic disorders. vaginal discharge ▶Frequency not known Myalgia
PDF page 1026
Manufacturer advises avoid—increased incidence of fetal abnormalities and death in animal studies.
PDF page 1026
Manufacturer advises avoid—present in milk in animal studies.
PDF page 1026
Manufacturer advises caution in mild to moderate impairment—risk of increased exposure; avoid in severe impairment—no information available.
PDF page 1026
Manufacturer advises caution if creatinine clearance less than 30 mL/minute—no information available.
PDF page 1026
500 mg dose should be administered as one 250-mg injection (slowly over 1–2 minutes) into each buttock.
PDF page 1026
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Faslodex (AstraZeneca UK Ltd) Fulvestrant 50 mg per 1 ml Faslodex 250mg/5ml solution for injection pre-filled syringes | 2 pre-filled disposable injection P £522.41 DT = £522.41
PDF page 1026
500 mg every 2 weeks for the first 3 doses, then
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1026